A Bayesian Meta-Analysis on Published Sample Mean and Variance Pharmacokinetic Data with Application to Drug–Drug Interaction Prediction

REFERENCES

• Bourrie , M. , Meunier , V. , Berger Y. , Fabre G. ( 1996 ). Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes . J. Pharmaco. Exper. Ther. 277 : 321 – 332 .
   PubMed Web of Science ®Google Scholar
• Breslow , N. E. , Clayton , D. G. ( 1993 ). Approximate inference in generalized linear mixed model . J. Am. Stat. Assoc. 88 : 9 – 25 .
   Web of Science ®Google Scholar
• Chien , J. Y. , Lucksiri , A. , Ernest , C. S. , Gorski , J. C. , Wrighton , S. A. , Hall , S. D. ( 2006 ). Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole . Drug Metab. Dispos. 34 : 1208 – 1219 .
   PubMed Web of Science ®Google Scholar
• Cleary , J. D. , Taylor , J. W. , Chapman , S. W. ( 1992 ). Itraconazole in antifungal therapy . Ann. Pharmacother. 26 : 502 – 509 .
   PubMed Web of Science ®Google Scholar
• Daneshmend , T. K. , Warnock , D. W. , Turner , A. , Roberts , C. J. (1981). Pharmacokinetics of ketoconazole in normal subjects. J. Antimicrob. Chemother. 8:299–304.
   PubMedGoogle Scholar
• Daneshmend , T. K. , Warnock , D. W. , Ene , M. D. , Johnson , E. M. , Parker , G. , Richardson , M. D. , Roberts , C. J. ( 1983 ). Multiple dose pharmaco-kinetics of ketoconazole and their effects on antipyrine kinetics in man . J. Antimicrob. Chemother. 12 : 185 – 188 .
   PubMed Web of Science ®Google Scholar
• Daneshmend , T. K. , Warnock , D. W. , Ene , M. D. , Johnson , E. M. , Potten , M. R. , Richardson , M. D. , Williamson , P. J. ( 1984 ). Influence of food on the pharmaco-kinetics of ketoconazole . Antimicrob. Agents Chemother. 25 : 1 – 3 .
   PubMedGoogle Scholar
• Davidian , M. , Giltinan , D. M. ( 1995 ). Nonlinear Models for Repeated Measurment Data . New York : Chapman and Hall .
   Google Scholar
• de Waziers , I. , Cugnenc , P. H. , Yang , C. S. , Leroux , J. P. , Beaune , P. H. ( 1990 ). Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues . J. Pharmacol. Exp. Ther. 253 : 387 – 394 .
   PubMed Web of Science ®Google Scholar
• FDA ( 1999 ). Bioequivalence Reviews. http://www.fda.gov/cder/foi/anda/99/75-273_Ketoconazole_bioeqr.pdf
   Google Scholar
• FDA ( 2006 ). Drug Drug Interaction Guideline . http://www.fdagov/cber/gdlns/interactionpdf .
   Google Scholar
• Gascoigne , E. W. , Barton , G. J. , Michaels , M. , Meuldermans , W. , Heykans , J. ( 1981 ). The kinetics of ketoconazole in animals and man . Clin. Res. Rev. 1 : 177 – 187 .
   Google Scholar
• Gelman , A. , Rubin , D. B. ( 1992 ). Inference from iterative simulation using multiple sequences . Statist. Sci. 7 : 457 – 472 .
   Google Scholar
• Gibbs , M. A. , Thummel , K. E. , Shen , D. D. , Kunze , K. L. ( 1999 ). Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression . Drug Metab. Dispos. 27 ( 2 ): 180 – 187 .
   PubMed Web of Science ®Google Scholar
• Hastings , W. K. ( 1970 ). Monte Carlo sampling methods using Markov chains and their applications . Biometrika 57 : 97 – 109 .
   Web of Science ®Google Scholar
• Huang , Y. C. , Colaizzi , J. L. , Bierman , R. H. , Woestenborghs , R. , Heykants , J. ( 1986 ). Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers . Antimicrob. Agents Chemother. 30 : 206 – 210 .
   PubMed Web of Science ®Google Scholar
• Ikkola , K. T. , Backman , J. T. , Neuvonen , P. J. ( 1994 ). Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole . Clin. Pharmacol. Ther. 55 : 481 – 485 .
   PubMedGoogle Scholar
• Ito , K. , Iwatsubo , T. , Kanamitsu , S. , Ueda , K. , Suzuki , H. , Sugiyama , Y. ( 1998 ). Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver . Pharmacol. Rev. 50 : 387 – 412 .
   PubMed Web of Science ®Google Scholar
• Lam , Y. W. , Alfaro , C. L. , Ereshefsky , L. , Miller , M. ( 2003 ). Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone . J. Clin. Pharmacol. 43 : 1274 – 1282 .
   PubMed Web of Science ®Google Scholar
• Lee , J. I. , Chaves-Gnecco , D. , Amico , J. A. , Kroboth , P. D. , Wilson , J. W. , Frye , R. F. ( 2002 ). Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping . Clin. Pharmacol. Ther. 72 : 718 – 728 .
   PubMed Web of Science ®Google Scholar
• Li , L. , Brown , M. B. , Lee , K. H. , Gupta , S. ( 2002 ). Estimation and inference for a spline-enhanced population pharmacokinetic model . Biometrics 58 : 601 – 611 .
   PubMed Web of Science ®Google Scholar
• Li , L. , Lin , X. , Brown , M. , Gupta , S. , Lee , K. H. ( 2004 ). A population pharmacokinetic model with time-dependent covariates measured with errors . Biometrics 60 : 451 – 460 .
   PubMedGoogle Scholar
• Li , L. , Yu , M. , Chin , R. , Lucksiri , A. , Flockhart , D. , Hall , S. ( 2007 ). Drug-drug interaction prediction: a Bayesian meta-analysis approach . Statistics in Medicine 26 : 3700 – 3721 .
   PubMed Web of Science ®Google Scholar
• Martinez-Jorda , R. , Rodriguez-Sasianin , J. M. , Calvo , R. ( 1990 ). Serum binding of ketoconazole in health and disease . Int. J. Clin. Pharmacol. Res. 5 : 271 – 276 .
   Google Scholar
• McCrea , J. , Prueksaritanont , T. , Gertz , B. J. , Carides , A. , Gillen , L. , Antonello , S. , Brucker , M. J. , Miller-Stein , C. , Osborne , B. , Waldman , S. ( 1999 ). Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity . J. Clin. Pharmacol. 39 : 1212 – 1220 .
   PubMed Web of Science ®Google Scholar
• Molenberghs , G. , Verbeke , G. (2005). Models for Discrete Longintudinal Data . New York : Springer.
   Google Scholar
• Monahan , B. P. , Ferguson , C. L. , Killeavy , E. S. , Lloyd , B. K. , Troy , J. , Cantilena , L. R. , Jr. ( 1990 ). Torsades de pointes occurring in association with terfenadine use . Jama 264 : 2788 – 2790 .
   PubMed Web of Science ®Google Scholar
• Okuda , H. , Nishiyama , T. , Ogura , K. , Nagayama , S. , Ikeda , K. , Yamaguchi , S. , Nakamura , Y. , Kawaguchi , Y. , Watabe , T. ( 1997 ). Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs . Drug Metab. Dispos. 25 : 270 – 273 .
   Web of Science ®Google Scholar
• Price , P. S. , Conolly , R. B. , Chaisson , C. F. , Gross , E. A. , Young , J. S. , Mathis , E. T. , Tedder , D. R. ( 2003 ). Modeling interindividual variation in physiological factors used in PBPK models of humans . Crit. Rev. Toxicol. 33 : 469 – 503 .
   PubMed Web of Science ®Google Scholar
• Rowland , M. , Tozer , T. N. ( 1995 ). Clinical Pharmacokinetics Concept and Applications . London : Lippincott Williams & Wilkins .
   Google Scholar
• Shimada , T. , Yamazaki , H. , Mimura , M. , Inui , Y. , Guengerich , F. P. ( 1994 ). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians . J. Pharmacol. Exp. Ther. 270 : 414 – 423 .
   PubMed Web of Science ®Google Scholar
• Tsunoda , S. M. , Velez , R. L. , von Moltke , L. L. , Greenblatt , D. J. ( 1999 ). Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole . Clin. Pharmacol. Ther. 66 : 461 – 471 .
   PubMed Web of Science ®Google Scholar
• von Moltke , L. L. , Greenblatt , D. J. , Duan , S. X. , Harmatz , J. S. , Shader , R. I . ( 1994 ). In vitro prediction of the terfenadine-ketoconazole pharmacokinetics interaction . J. Clin. Pharmacol. 34 : 1222 – 1227 .
   PubMed Web of Science ®Google Scholar
• von Moltke , L. L. , Greenblatt , D. J. , Schmider , D. J. , Duan , S. X. , Wright , C. E. , Harmatz , J. S. , Shader , R. I . ( 1996 ). Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxitine, norfluxetine, and by azole antifungal agents . J. Clin. Pharmacol. 36 : 783 – 791 .
   PubMed Web of Science ®Google Scholar
• Wakefield , J. C. , Rahman , N. ( 2000 ). The combination of population pharmacokinetic studies . Biometrics 56 : 263 – 270 .
   PubMed Web of Science ®Google Scholar
• Watabe , T. ( 1996 ). Strategic proposals for predicting drug-drug interactions during new drug development: Based on sixteen deaths caused by interactions of the new antiviral sorivudine with 5-fluorouracil prodrugs . J. Toxicol. Sci. 21 : 299 – 300 .
   PubMedGoogle Scholar
• Wolfinger , R. , O'Connell , M. ( 1993 ). Generalized linear mixed models: a pseudo-likelihood approach . J. Stat. Comp. Sim. 48 : 233 – 243 .
   Web of Science ®Google Scholar
• Wrighten , S. A. , Ring , B. J. ( 1994 ). Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine . Pharm Res. 11 : 921 – 924 .
   PubMedGoogle Scholar
• Yang , J. , Kjellsson , M. , Rostami-Hodjegan , A. , Tucker , G. T. ( 2003 ). The effects of dose staggering on metabolic drug-drug interactions . Eur. J. Pharm. Sci. 20 : 223 – 232 .
   PubMed Web of Science ®Google Scholar